Missed Opportunities for HIV Screening in General Practice (DepVIH)

December 30, 2025 updated by: University Hospital, Strasbourg, France

Missed Opportunities for HIV Screening in General Practice - A Retrospective Study

The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the barriers to testing.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Strasbourg, France, 67091
        • Recruiting
        • Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
        • Contact:
        • Principal Investigator:
          • Baptiste Hoellinger, MD
        • Principal Investigator:
          • Camille PFLEIDERER, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult subject (≥18 years) diagnosed with HIV infection between January 1, 2021, and July 30, 2024

Description

Inclusion Criteria:

  • Adult subject (≥18 years)
  • diagnosed with HIV infection between January 1, 2021, and July 30, 2024

Exclusion Criteria:

-Subject who arrived in France in the year preceding or during the period between January 1, 2024, and July 30, 2024.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Presence or absence of clinical signs suggestive of HIV infection
Time Frame: 1 year preceding HIV diagnosis
This is a retrospective analysis of data on the presence or absence of clinical signs suggestive of HIV infection during the year preceding diagnosis
1 year preceding HIV diagnosis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 14, 2025

Primary Completion (Estimated)

July 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

December 11, 2025

First Submitted That Met QC Criteria

December 11, 2025

First Posted (Estimated)

December 24, 2025

Study Record Updates

Last Update Posted (Actual)

January 5, 2026

Last Update Submitted That Met QC Criteria

December 30, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 9478

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Russia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe